Investor Relations

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Corporate Profile

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company is in early stages of developing methods for in vivo engineering to treat solid tumors. The Company is also applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.

Stock Information

Minimum 15 minutes delayed. Source: LSEG

Press Releases

26 Feb '26
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45, for patients with HLA types A*01:01 and A*03:01 Plans to initiate Phase 1 study of both...

View All

Latest Presentations

Events

View All

SEC Filings

Filing date Description Form
Report of unscheduled material events or corporate event 8-K
Annual report which provides a comprehensive overview of the company for the past year 10-K
Securities offered to employees pursuant to employee benefit plans S-8
View All